Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Other income (expense), net
Interest income	$ 4,300,000	$ 6,700,000	$ 8,000,000	$ 15,600,000
Interest expense	(8,400,000)	(9,000,000)	(17,600,000)	(17,300,000)
Impairments of investments	(5,500,000)	(1,200,000)	(6,800,000)	(17,000,000)
Foreign exchange gain (losses), net	(600,000)	(700,000)	(1,000,000)	300,000
Gain (loss) on sales of investments, net	200,000	6,300,000	15,500,000	11,300,000
Other, net	(1,700,000)	(1,100,000)	100,000	(300,000)
Total other income (expense), net	(11,728,000)	1,012,000	(1,777,000)	(7,373,000)
Other current assets
Deferred tax assets	66,900,000		66,900,000		112,200,000
Prepaid taxes	33,100,000		33,100,000		31,400,000
Receivable from collaborations	8,800,000		8,800,000		7,300,000
Interest receivable	6,100,000		6,100,000		4,900,000
Other prepaid expenses	60,100,000		60,100,000		47,900,000
Other	26,800,000		26,800,000		12,100,000
Total other current assets	201,794,000		201,794,000		215,822,000
Accrued Expenses and Other
Employee compensation and benefits	134,300,000		134,300,000		159,700,000
Revenue-related rebates	112,400,000		112,400,000		105,300,000
Restructuring charges	8,900,000		8,900,000		66,400,000
Royalties and licensing fees	40,000,000		40,000,000		45,100,000
Deferred revenue	59,100,000		59,100,000		41,300,000
Collaboration expenses	57,100,000		57,100,000		31,600,000
Clinical development expenses	33,700,000		33,700,000		24,400,000
Interest payable	21,600,000		21,600,000		21,600,000
Construction in progress accrual	13,300,000		13,300,000		16,400,000
Current portion of contingent consideration	4,900,000		4,900,000		11,900,000
Derivative liability	24,900,000		24,900,000		12,200,000
Other	131,100,000		131,100,000		130,000,000
Total accrued expenses and other	$ 641,273,000		$ 641,273,000		$ 665,923,000